ASCO Update: BMS' Nivolumab, Merck KGaA's ERBITUX, Amgen's T-Vec, Pfizer's XALKORI, GSK's VOTRIE

New Stories

• WA Budget includes significant investments in health and medical research

  June 20, 2025 - - Latest News

• Gilead confirms Australian submission for major HIV innovation following US approval

  June 20, 2025 - - Latest News

• Advocate and founder of Rare Cancers Australia steps down as chair

  June 20, 2025 - - BioPharma

• Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant

  June 19, 2025 - - Latest News

• Amplia announces second confirmed complete response in ACCENT trial

  June 19, 2025 - - Australian Biotech

• NZ Government expands access to melatonin and psilocybin

  June 18, 2025 - - Latest News

• Imugene announces US patent allowance for onCARlytics

  June 18, 2025 - - Australian Biotech